Amundi
CCCC icon

Amundi’s C4 Therapeutics CCCC Stock Holding History

Amundi’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,023
Closed -$9.19K – 2045
2023
Q1 		$9.19K Hold
3,023
– – ﹤0.01% 2006
2022
Q4 		$25.7K Hold
3,023
– – ﹤0.01% 1776
2022
Q3 		$27K Buy
+3,023
New +$31.4K ﹤0.01% 1731

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Amundi's CCCC Position: Q2 2023 in Review

Amundi sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 3,023 shares — an estimated $9.19K sold.

Amundi first reported a position in CCCC in Q3 2022 and held it in 3 quarters. The position peaked at $27K in Q3 2022. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Amundi reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Amundi sold 3,023 C4 Therapeutics shares in Q2 2023, an estimated $9.19K.
  • Amundi first reported a position in C4 Therapeutics in Q3 2022 and held it in 3 quarters.
  • Amundi's C4 Therapeutics position peaked at $27K in Q3 2022.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.